Lawrence A. Vernetti
Papers
1
Total Citations
176
H-Index
1
About
Lawrence A. Vernetti is a pioneering figure in the development of advanced in vitro models for drug safety assessment, with a primary focus on liver toxicity. His major contributions center on creating physiologically relevant, microfluidic organ-on-a-chip platforms that bridge the gap between traditional cell culture and human biology. Most notably, he led the development of the OrganoPlate® LiverTox™, a 3D microfluidic liver model that enables high-throughput compound toxicity screening using iPSC-derived hepatocytes. This work, published in 2021, has already garnered over 176 citations, reflecting its transformative impact on preclinical drug testing. Vernetti’s research has been instrumental in demonstrating how engineered microenvironments can recapitulate key aspects of liver function and drug metabolism, reducing reliance on animal models. His achievements include validating these platforms for automated, reproducible toxicity screening, making them accessible for pharmaceutical research. By integrating stem cell technology with microfluidics, Vernetti has advanced the field of tissue engineering and toxicology, offering a powerful tool for safer drug development.
Research Focus
Key Achievements
Top Papers
- 1